MCID: HR2001
MIFTS: 10

Her2-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Her2-Receptor Positive Breast Cancer

MalaCards integrated aliases for Her2-Receptor Positive Breast Cancer:

Name: Her2-Receptor Positive Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060079

Summaries for Her2-Receptor Positive Breast Cancer

MalaCards based summary : Her2-Receptor Positive Breast Cancer An important gene associated with Her2-Receptor Positive Breast Cancer is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Paclitaxel and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include breast and brain.

Related Diseases for Her2-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Her2-Receptor Positive Breast Cancer

Drugs & Therapeutics for Her2-Receptor Positive Breast Cancer

Drugs for Her2-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
2
Capecitabine Approved, Investigational Phase 3,Phase 1,Phase 2 154361-50-9 60953
3
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5
Lapatinib Approved March 2007, Investigational Phase 3,Phase 1,Phase 2 231277-92-2, 388082-78-8 208908 9941095
6 Albumin-Bound Paclitaxel Phase 3,Phase 2
7 Antimitotic Agents Phase 3,Phase 2
8 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
9 taxane Phase 3,Phase 2,Phase 1
10 Antimetabolites Phase 3,Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
12 Hormone Antagonists Phase 3
13 Hormones Phase 3
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
15 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
16 Angiogenesis Inhibitors Phase 3
17 Angiogenesis Modulating Agents Phase 3
18 Aromatase Inhibitors Phase 3
19 Estrogen Antagonists Phase 3
20 Estrogens Phase 3
21 Steroid Synthesis Inhibitors Phase 3
22
Everolimus Approved Phase 2 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
25
Trastuzumab Approved, Investigational Phase 2,Phase 1,Early Phase 1 180288-69-1 9903
26
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
27
Epirubicin Approved Phase 2 56420-45-2 41867
28
Adenosine Approved, Investigational Phase 2 58-61-7 60961
29
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
30
Gemcitabine Approved Phase 2 95058-81-4 60750
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Doxil Approved June 1999 Phase 2 31703
33 Anti-Bacterial Agents Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Antifungal Agents Phase 2
36 Anti-Infective Agents Phase 2
37 Immunosuppressive Agents Phase 2
38 Alkylating Agents Phase 2
39 Antirheumatic Agents Phase 2
40 Topoisomerase Inhibitors Phase 2
41 Antibodies Phase 2
42 Antibodies, Monoclonal Phase 2
43 Immunoglobulins Phase 2
44 Ado-trastuzumab emtansine Phase 2
45 Adrenergic beta-Antagonists Phase 2
46 Angiotensin-Converting Enzyme Inhibitors Phase 2
47 Maytansine Phase 2
48 Mitogens Phase 2
49 Antiviral Agents Phase 2

Interventional clinical trials:

(show all 20)

id Name Status NCT ID Phase Drugs
1 A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Recruiting NCT02973737 Phase 3 pyrotinib;placebo;Capecitabine
2 Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Not yet recruiting NCT03080805 Phase 3 Pyrotinib Plus Capecitabine;Lapatinib Plus Capecitabine
3 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer Terminated NCT01303679 Phase 3 Paclitaxel;Bevacizumab;Exemestane
4 A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer Completed NCT00411788 Phase 2 Rapamycin;Trastuzumab
5 Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy Completed NCT01594177 Phase 2 Afatinib;Trastuzumab;Paclitaxel;Epirubicin;Cyclophosphamide
6 NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer Completed NCT01816594 Phase 2 BKM120;Trastuzumab;Paclitaxel;Placebo
7 Cardiac Safety Study in Patients With HER2 + Breast Cancer Recruiting NCT01904903 Phase 2 Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine
8 HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 Recruiting NCT01565200 Phase 2 T-DM1
9 Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Active, not recruiting NCT01912963 Phase 2 Pertuzumab, Trastuzumab and Eribulin
10 Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy Active, not recruiting NCT02252887 Phase 2 Gemcitabine;Trastuzumab;Pertuzumab
11 Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Active, not recruiting NCT01796197 Phase 2 Trastuzumab;Pertuzumab;Paclitaxel;Doxorubicin;Cyclophosphamide
12 A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab Active, not recruiting NCT02422199 Phase 1, Phase 2 pyrotinib;Lapatinib;capecitabine
13 A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer Withdrawn NCT01137994 Phase 2 Lapatinib;Docetaxel;Paclitaxel;Vinorelbine
14 Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients Completed NCT01420146 Phase 1 Zr89-trastuzumab
15 Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer Recruiting NCT02361112 Phase 1 pyrotinib combined with capecitabine
16 ARRY-380 + Trastuzuamab for Breast w/ Brain Mets Active, not recruiting NCT01921335 Phase 1 ARRY-380 Twice Daily Dosage;ARRY-380 Once Daily;Trastuzumab
17 Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer Active, not recruiting NCT01937689 Phase 1 Pyrotinib
18 Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer Terminated NCT01301911 Phase 1 Cipatinib
19 89ZrTrastuzumab Breast Imaging With Positron Emission Tomography Recruiting NCT02065609 Early Phase 1 89Zr-Trastuzumab Human Dosimetry and Safety;HER2 Positive Lesion Detection and Safety
20 Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer Recruiting NCT02875951

Search NIH Clinical Center for Her2-Receptor Positive Breast Cancer

Genetic Tests for Her2-Receptor Positive Breast Cancer

Anatomical Context for Her2-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Her2-Receptor Positive Breast Cancer:

39
Breast, Brain

Publications for Her2-Receptor Positive Breast Cancer

Variations for Her2-Receptor Positive Breast Cancer

Expression for Her2-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Her2-Receptor Positive Breast Cancer.

Pathways for Her2-Receptor Positive Breast Cancer

GO Terms for Her2-Receptor Positive Breast Cancer

Sources for Her2-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....